Physician and payer perspectives on oral type 2 diabetes therapies in China and South Korea

China has the largest prevalent population of type 2 diabetes in the world and an ever-expanding affluent middle class, while South Korea has one of the most advanced healthcare systems in the world, notes a new report from health care advisory firm Decision Resources.

The very low risk of hypoglycemia and excellent tolerability associated with DPP-IV inhibitors make this class suitable for widespread use for type 2 diabetes, but high-cost brands face unique market access challenges in each of these markets, it says.

Availability of DPP-IV inhibitors